Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02289222Phase 2Terminated
- Start
- Dec 2014
- Primary completion
- Aug 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in multiple myeloma (MM). Started Dec 2014; status: terminated.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02289222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289222.